Disease-modifying therapy
Outcome of MS relapses in the era of disease-modifying therapy
... (onset, disease-modifying therapy (DMT), latest neurological evaluation before current relapse), charac- teristics of the current relapse (symptoms, Kurtzke’s Expanded Disability Status Scale (EDSS) ...
8
Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study
... Figure 2 shows a graphical representation of preferences by means of the distance between patients’ stated preferences: white dots represent the responses of each participant with their corresponding numerical ...
5
Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
... Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly- used drugs as well. ...
8
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis
... We found that IHD and anxiety were strongly associated with a decreased likelihood of initiating a DMT. Other conditions, such as hyperlipidemia, chronic lung diseases, and bipolar disorder, also ex- hibited similar ...
10
Allergen-specific immunotherapy
... potentially disease-modifying therapy that is effective for the treatment of allergic rhinitis/conjunctivitis, allergic asthma and stinging insect ...pharmacological therapy, the amount and ...
7
Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat to target escalation of therapy in rheumatoid arthritis
... clinical disease activity and MRI joint inflammation, and has emphasized that the goal of complete imaging resolution of inflammation is far off in the majority of real-world ...
9
Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease modifying anti rheumatic drugs: a register based study
... respiratory disease, heart failure, depression, malignancy and older age were all associated with no present bDMARDs in this ...bDMARDs therapy will automatically lead to lower frequency of malignancies and ...
10
Comparative effectiveness of beta interferons and glatiramer acetate for relapsing remitting multiple sclerosis : systematic review and network meta analysis of trials including recommended dosages
... Longer-term observational cohorts have also examined DMT effectiveness over time and shed some doubt on the findings from randomised trials. In the year 8 ana- lyses from the UK Risk Sharing Scheme, DMTs were not found ...
17
Upadacitinib improves patient reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease modifying antirheumatic drugs: results from SELECT NEXT
... joint disease that is associated with substantial clinical burden ...RA disease activity that need to improve in patient-perceived remission ...of disease, pain, physical func- tion, fatigue, HRQOL, ...
11
Caught in a no-win situation: discussions about CCSVI between persons with multiple sclerosis and their neurologists – a qualitative study
... This paper explores the discussions that took place be- tween PwMS and their neurologists following the release of news of Zamboni’s hypothesis. We investigate these conversations about CCSVI against the backdrop of the ...
17
Early combination disease modifying antirheumatic drug therapy and tight disease control improve long term radiologic outcome in patients with early rheumatoid arthritis: the 11 year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
... low disease activity at 11 years had received sig- nificantly shorter periods of combination DMARDs between 2 and 11 years than had the patients who had high disease activity at 11 years ...severe ...
8
Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey
... demographics, disease severity, symptoms, and health care resource and DMT ...their disease as more severe, reporting several neurological symptoms more frequently and higher hospitalization rates than RRMS ...
9
Motivations for inadequate persistence with disease modifying anti rheumatic drugs in early rheumatoid arthritis: the patient’s perspective
... Patient’s perception of at least “some difficulty to find arthritis medication” (previously reported as lack of availability at the drug store) and that “arthritis medica- tion is expensive” (lack of financial resources) ...
8
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis
... the disease course in the individual patient and, hence, the treat- ment requirements at the onset of the disease [13, 21], a step-up approach is generally pursued of starting MTX and adding a biologic ...
8
The importance of collecting structured clinical information on multiple sclerosis
... baseline Expanded Disability Status Scale (EDSS) score, prior relapse rate and disease duration. The type of regres- sion model used largely depends on the outcome being measured [22]. Logistic regression is ...
9
“Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti tumor necrosis factor alpha drugs: a nested case–control study”
... improve long-term outcomes [3]. RA patients have an increased lifetime risk for cardiovascular disease [4] and are at greater risk of developing infections [5-7]. The problem of increased infections and higher ...
7
Disease-modifying drugs in Alzheimer's disease
... renal disease (due to its elimination pattern), mild or moderate liver disease (mainly metabolized by the liver), sick sinus syn- drome, conduction abnormalities, gastric or duodenal ulcers, or a history of ...
9
Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients
... Physicians often struggle to accurately assess patient preferences [16] and may rely on their own preferences and cognitive distortions (e.g. overconfidence, tolerance to risk and ambiguity) to make treatment recommenda- ...
11
Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence
... tween the whole-lung densities of those who died and those who survived [34]. The authors also state that it is unsurprising a mortality difference has not been ob- served in clinical trials, as their Kaplan Meier plots ...
9
Mitochondrial therapy for Parkinson’s disease: Neuroprotective pharmaconutrition may be disease-modifying
... “Mitochondrial therapy”, both preventive and immediate, is a relatively new concept, and inroads have been significant, not only in neurologic disease but also in the intensive care unit, and in cardiology, ...
14